Microplastics heart disease, Microplastics and blood vessels
In recent years, micro- and nanoplastics have emerged as a growing focus of scientific and public health attention. In addition to this, in the last couple of years, multiple human studies have found plastic particles inside arterial plaque, within the walls of major blood vessels, and even in heart tissue itself. One landmark clinical study reported that people whose carotid-artery plaques contained micro/nanoplastics had a significantly higher risk of heart attack, stroke, or death over ~3 years than people whose plaque showed no plastics. That’s the first prospective signal in humans that the plastic problem may reach all the way to our cardiovascular risk.
https://pubmed.ncbi.nlm.nih.gov/38446676/
Below, we describe what microplastics are, how they get into the body, what the best human evidence shows so far, the most plausible biological mechanisms, and what you can realistically do about exposure.
What exactly are microplastics and nanoplastics?
- Microplastics are plastic fragments typically <5 mm in size (down to micrometres);
- Nanoplastics are even smaller (generally <1 μm).
They shed from consumer items (bottles, food containers), synthetic clothing, tyres, paints, and more. Because they’re so small, they can be inhaled (indoor dust, outdoor air) or ingested (food, bottled water, seafood, salt, tea from plastic tea bags, etc.). Once inside, a fraction appears able to cross biological barriers into the bloodstream and tissues. Three reviews (links below) in 2024 described detections of microplastics across multiple human tissues, while also stressing uncertainties in measurement and health impact.
https://jogh.org/2024/jogh-14-04179
https://www.frontiersin.org/journals/toxicology/articles/10.3389/ftox.2024.1479292/full
https://academic.oup.com/eurheartj/article/45/38/4099/7750375
Direct findings in human hearts and arteries
Microplastics in human heart tissue
In 2023, a pilot study of patients undergoing cardiac surgery found microplastics in multiple heart tissues and in the perioperative blood specimens. While small and exploratory, this finding made clear that plastic particles can reach and persist in cardiac tissues. The authors concluded: The detection of poly(methyl methacrylate) in the left atrial appendage, as well as in epicardial and pericardial adipose tissues, cannot be explained by accidental surgical exposure, offering clear evidence of microplastics already present in patients undergoing cardiac surgery.”
https://pubmed.ncbi.nlm.nih.gov/37440474/
Microplastics and blood vessels
In 2024, a team reported microplastics in three types of human arteries—carotid (neck), coronary (heart), and aorta (the body’s main artery. Microplastics were present in all 17 arterial samples analysed. The authors found that the concentration of microplastics in arteries with atherosclerotic plaques—both in the coronary and carotid arteries—was markedly higher than in aortas without plaques, suggesting a potential link between microplastics and atherosclerosis in humans.
https://pubmed.ncbi.nlm.nih.gov/37440474/
A prospective signal: plastics in plaque and future events
The robust study to date (published in the New England Journal of Medicine in 2024) examined carotid endarterectomy specimens. Participants of a study, in whom MicroPLASTICs and NanoPLASTICs were present had a higher risk of Myocardial Infarction (heart attack), stroke or death of any cause (composite endpoint). This research data was published in March 2024 in New England Journal of Medicine and included 257 individuals who were followed up for ~34 months. The samples were taken from patients carotid plaques, when they were undergoing carotid endarterectomy. Study participants had no symptoms of carotid artery disease. Individuals with detected MicroPLASTICs and NanoPLASTICs had a higher composite end-point of myocardial infarction, stroke and death of any cause. (HR 4.53, 95% CI, 2-10.27, p<0.001).
So in essence, patients whose plaques contained micro- and nanoplastics had higher hazards of a myocardial infarction, stroke, or death at a median 34 months than those with plastic-free plaques, even after adjustments. The work does not prove causation, but it’s the first human study to link particle presence in plaques with subsequent clinical events.
https://pubmed.ncbi.nlm.nih.gov/38446676/
To summarise, several independent teams have detected plastics in human arteries, plaques, and heart tissue, and at least one prospective study linked their presence in plaque to worse cardiovascular outcomes. That is why “Microplastics heart disease” is no longer a speculative question—it’s an active research question with early, consequential human data.
How might these particles harm the cardiovascular system?
Researchers are converging on several biologically plausible mechanisms—each already familiar in vascular medicine:
- Endothelial dysfunction
The endothelium (the inner lining of blood vessels) governs tone, permeability, and anti-thrombotic balance. Experimental studies indicate that micro/nanoplastic exposure can disrupt endothelial cells, impair nitric-oxide signalling, and increase permeability—conditions that favour atherosclerosis.
https://www.frontiersin.org/journals/toxicology/articles/10.3389/ftox.2024.1479292/full
- Oxidative stress and inflammation
Microplastics can provoke inflammatory reactions, which is a classic driver of plaque formation and instability.
https://particleandfibretoxicology.biomedcentral.com/articles/10.1186/s12989-024-00596-4
- Potential microthrombi formation
Any surface that activates platelets or the coagulation cascade can tilt the system toward thrombosis. While direct, causal evidence in humans is lacking, in vitro signals suggest particle–platelet interactions are possible and warrant study (summarised across reviews).
https://www.frontiersin.org/journals/toxicology/articles/10.3389/ftox.2024.1479292/full
So far, the evidence tells us:
1) Prospective outcome data:
- Microplastics and Nanoplastics in Atheromas and Cardiovascular Events (NEJM, 2024):
Patients with micro/nanoplastics in their plaque experienced higher rates of MI, stroke, or death over ~34 months than those without detected plastics, even after adjusting for traditional risk factors. The polymer types included polyethylene and PVC, among others. Limitations include potential confounding, surgical population selection, and unknown exposure timing.
https://pubmed.ncbi.nlm.nih.gov/38446676/
2) Direct tissue detection (moderate weight)
- Heart tissue (cardiac surgery patients): Multiple microplastic types were found pre- and post-surgery. As a pilot study without outcomes, it shows presence, not pathogenicity.
https://pubmed.ncbi.nlm.nih.gov/37440474/
- Arterial walls and plaques across vessels: The 2024 Microplastics in three types of human arteries detected by pyrolysis-gas chromatography/mass spectrometry (Py-GC/MS) study detected plastics in carotid, coronary, and aortic tissue samples. Again, presence does not equal harm, but it sets the stage for larger, better-controlled analyses.
https://pubmed.ncbi.nlm.nih.gov/38428296/
3) Biomonitoring in blood (supporting evidence)
- Microplastics in human blood: Polymer types, concentrations and characterisation using μFTIR (2024): Work cataloguing polymer types, sizes, and shapes in human blood supports the plausibility of vascular exposure and transport. The authors concluded: This study reinforces the growing evidence that microplastics can enter the human body and circulate through the bloodstream. The diversity in particle shapes and sizes raises important concerns about their presence and potential risks, including vascular inflammation, accumulation in major organs, and alterations in immune responses, haemostasis, and thrombosis.
https://www.sciencedirect.com/science/article/pii/S0160412024003374
4) Ecological and environmental associations (hypothesis-generating)
- One analysis linked marine microplastic levels to cardiometabolic disease prevalence— consistent with the overall concern that high-plastic environments may correlate with cardiovascular risk.
https://www.ahajournals.org/doi/10.1161/JAHA.124.039891
What we still don’t know? Our uncertainties are as significant as our current knowledge.
- The dose–response relationship (how much exposure meaningfully changes risk).
- The critical particle sizes and polymer types most relevant to vascular harm.
- Whether plastics primarily accelerate atherosclerosis, destabilise existing plaques, or drive pro-thrombotic effects (or all three).
- The time course: Do particles accumulate over years, and can burden be reduced if exposure drops?
From particles to pathology: a step-by-step plausibility map
- Exposure: daily ingestion/inhalation (food, water, dust, air).
- Translocation: particles cross gut or lung barriers into circulation (supported by blood detections).
- Vascular deposition: particles lodge in the intima or within developing plaques (artery and plaque detections).
- Local effects: oxidative stress, inflammation, immune activation.
- Clinical expression: accelerated plaque growth, cap weakening, thrombosis—manifesting as myocardial infarction or stroke (suggested by the hazard signal in the NEJM study from 2024). https://pubmed.ncbi.nlm.nih.gov/38446676/
This pathway remains a possibility, but not a proof, albeit it mimics “classical” atherothrombotic biology.
What better research may look like:
- Standardised measurement: Harmonised sampling, contamination control, and spectroscopy protocols for blood, plaque, and tissue. This will make cross-study comparisons defensible.
- Prospective cohorts with exposure quantification: Repeated measures of blood/tissue plastics, paired with careful tracking of clinical events.
- Interventional studies: Can reducing ingestion/inhalation lower blood or plaque burdens? And does that translate to improved endothelial function or fewer events?
- Mechanistic human studies: Vascular imaging (e.g., PET for inflammation), endothelial function testing, and transcriptomic profiling in patients stratified by plastic burden.
Frequently asked questions
Is the hazard as big as smoking or high LDL?
Based on what we know now, most likely not. Classic risk factors still dominate. But plastics may be an additive risk—another push on the same biological pathways.
Should I get “tested” for microplastics?
To our knowledge, no validated clinical test exists yet for routine care.
Does bottled water drive most exposure?
It’s a contributor, but not the only one. Diet, indoor air/dust, and packaging all matter.
Practical current advice for clinicians and patients
For clinicians, the key takeaway is to manage the well proven risk factors, such as lowering LDL, managing blood pressure and glucose, supporting smoking cessation, encouraging physical activity, and addressing sleep and stress—while keeping up with emerging evidence about microplastics.
For patients, apart from the above, it`s reasonable to take practical steps to reduce exposure, such as minimizing contact with hot plastics and limiting unnecessary single-use bottles, while also avoiding unproven claims and products. Ultimately, the best protection for heart health is already well established: a Mediterranean type of diet, regular exercise, and careful management of risk factors—now complemented perhaps by more mindful plastic use.
Final word
The possibility that Microplastics and blood vessels interact appears to be shown in the above studies, because we have tissue detections in arteries and hearts. We have one observational, prospective association with hard cardiovascular events, and we have a mechanistic theory, which makes sense to cardiologists.
The science is still incomplete—especially on dose–response and causality—therefore more research in this field would be super interesting. For now as per above paragraph we have several other risk factors that we can focus on, while watching this space.
Notes on interpretation
- Associations do not prove causation. The strongest human evidence so far (NEJM 2024) remains observational, though prospective. Therefore we are waiting for more data.
